Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes

Baxter International Inc. (NYSE: BAX) announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids (fats and cholesterol). The combined results were presented as a late-breaking presentation at the 49th Annual European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) congress in Paris.

Results from the combined IMPENDIA/EDEN trials showed that a low-glucose PD regimen led to clinically and statistically significant reductions in serum levels of HbA1c (the standard marker for assessing blood glucose control) in adult PD patients with diabetes. In the studies, significant reductions also were seen with certain lipid parameters including serum triglycerides (type of lipid or fat found in the blood), VLDL-cholesterol and apolipoprotein B (a protein that helps form LDL, or bad cholesterol, in blood) following a low-glucose PD regimen.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• EU approves Acadia's trofinetide for Rett syndrome treatment
• Nu Skin EVP of global sales takes medical leave
• Alibaba prices HK$80 billion share placement in Hong Kong